Real-World Experience with Bezlotoxumab for Prevention of Recurrence of <em>Clostridioides difficile</em> Infection

Real-World Experience with Bezlotoxumab for Prevention of Recurrence of <em>Clostridioides difficile</em> Infection

Bezlotoxumab is marketed for the prevention of recurrent <i>Clostridioides difficile</i> infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness an...

Full description

Bibliographic Details
Main Authors: Rosa Escudero-Sánchez, María Ruiz-Ruigómez, Jorge Fernández-Fradejas, Sergio García Fernández, María Olmedo Samperio, Angela Cano Yuste, Angela Valencia Alijo, Beatriz Díaz-Pollán, María Jesús Rodríguez Hernández, Esperanza Merino De Lucas, Oriol Martín Segarra, Carmen Sáez Bejar, Carlos Armiñanzas Castillo, Belén Gutiérrez-Gutiérrez, Dolors Rodríguez-Pardo, Antonio Ramos-Martínez, Julián Torre-Cisneros, Francisco López-Medrano, Javier Cobo Reinoso
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Journal of Clinical Medicine
Subjects:
<i>Clostridium difficile</i>
<i>Clostridioides difficile</i>
<i>C. difficile</i> infection
bezlotoxumab
recurrence
Online Access:https://www.mdpi.com/2077-0383/10/1/2

Similar Items

Similar Items